Press Releases

COLUMBIA, Md., Aug 04, 2008 (BUSINESS WIRE) -- Osiris Therapeutics, Inc. (NASDAQ:OSIR), the leader in stem cell therapeutics, announced today that it will report its financial results for the quarter ended June 30, 2008, on Thursday, August 7, 2008. C. Randal Mills, Ph.D., President and Chief Executive Officer, and Richard Hunt, Chief Financial Off...  

COLUMBIA, Md., Jul 24, 2008 (BUSINESS WIRE) -- Osiris Therapeutics, Inc. (NASDAQ:OSIR) today announced that it has closed its definitive agreement with NuVasive, Inc. (NASDAQ:NUVA) for the purchase of the Osteocel business in a transaction worth up to $137 million. Osiris shareholders approved the transaction; shareholder approval was the last majo...  

COLUMBIA, Md., Jun 18, 2008 (BUSINESS WIRE) -- Osiris Therapeutics, Inc. (NASDAQ:OSIR), a leading stem cell therapeutic company focused on developing and marketing products to treat medical conditions in the inflammatory, orthopedic, and cardiovascular areas, announced today that C. Randal Mills, Ph.D., President and CEO, is scheduled to present at...  

COLUMBIA, Md., Jun 09, 2008 (BUSINESS WIRE) -- Osiris Therapeutics, Inc. (NASDAQ:OSIR), a leading stem cell therapeutic company focused on developing and marketing products to treat medical conditions in the inflammatory, orthopedic, and cardiovascular areas, announced today that C. Randal Mills, Ph.D., President and CEO, is scheduled to present at...  

COLUMBIA, Md., May 21, 2008 (BUSINESS WIRE) -- Osiris Therapeutics, Inc. (NASDAQ:OSIR) today announced the treatment of the first patients in a new Phase II clinical trial evaluating Prochymal, a mesenchymal stem cell (MSC) therapy, for moderate to severe Chronic Obstructive Pulmonary Disease (COPD). This trial marks the sixth indication for which ...